Category Archives : Allgemein

Home  >>  Allgemein

DKFZ: Succession of DKFZ Chairman and Scientific Director open

On Juli 15, 2015, Posted by , In Allgemein, With No Comments

Wolfgang Wick to remain at Heidelberg University Hospital Heidelberg University Hospital and the German Cancer Research Center have announced that, following a short period of negotiations, the Medical Director of the Department of Neurology at Heidelberg University Hospital, Professor Dr. Wolfgang Wick, will no longer be assuming the position of…

Cancer Research Consortium “IMMUNO-TRANSPORTER” funded by Federal Ministry of Education and Research

On Juni 12, 2015, Posted by , In Allgemein,News,Press Releases, With No Comments

Mainz, Heidelberg, Stuttgart June 2015 – The newly established "IMMUNO-TRANSPORTER" consor-tium will collaborate to develop innovative approaches in the field of cancer immunotherapy. The collaboration is made possible through funding by the Federal Ministry of Education and Research (BMBF) within the program “Efficient drug delivery in biological systems – BioMatVital:…

BioRN: Maastricht joins the Health Axis Europe

On Juni 12, 2015, Posted by , In Allgemein,News,Press Releases, With No Comments

The health research region Maastricht joins the Health Axis Europe. The four leading locations Cambridge (UK), Leuven (Belgium), Maastricht (Netherlands), and Heidelberg (Germany) form an alliance to foster innovation in health across Europe. Heidelberg (Germany) | During a visit by a delegation of the Employers’ Association of the Province of…

Roche’s Perjeta regimen helped people with HER2-positive early breast cancer live longer without their disease returning or getting worse compared to Herceptin and chemotherapy

On Juni 1, 2015, Posted by , In Allgemein, With No Comments

New data from Phase II NeoSphere study provide additional evidence on the role of Perjeta in the neoadjuvant (pre-surgery) treatment of HER2-positive early breast cancer (eBC) Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new results from the Phase II NeoSphere study. The results suggest that Perjeta® (pertuzumab) in combination…

Updated data showed Roche’s investigational combination of cobimetinib and Zelboraf (vemurafenib) helps people with advanced melanoma live for a year without their disease worsening

On Mai 30, 2015, Posted by , In Allgemein, With No Comments

Phase III coBRIM study demonstrated a median progression-free survival of 12.3 months with cobimetinib plus Zelboraf Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced follow-up data from two studies of the investigational MEK inhibitor cobimetinib in combination with Zelboraf® (vemurafenib). Updated data from the pivotal coBRIM Phase III study showed…

Roche’s Gazyva/Gazyvaro extended the time people with refractory indolent non-Hodgkin’s lymphoma lived without their disease worsening

On Mai 30, 2015, Posted by , In Allgemein, With No Comments

GADOLIN is the second positive phase III study in the Gazyva/Gazyvaro clinical development programme Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the Phase III GADOLIN study showing that Gazyva®/Gazyvaro® (obinutuzumab) plus bendamustine followed by Gazyva/Gazyvaro alone provided significant benefit for people with indolent non-Hodgkin’s lymphoma (NHL) that…

Roche to announce new data in rheumatoid arthritis and severe inflammatory disorders at the European League Against Rheumatism Annual Congress (EULAR 2015)

On Mai 27, 2015, Posted by , In Allgemein, With No Comments

40 data presentations across 7 autoimmune conditions, including new results from RoACTEMRA in early RA and systemic sclerosis (SSc) – a potentially fatal disease with limited treatment options1 Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data in rheumatoid arthritis (RA) and other severe autoimmune conditions will be…

EMBL: Oceans endeavour charts 40 million genes

On Mai 21, 2015, Posted by , In Allgemein, With No Comments

Sailing boat expedition reveals new insights into climate change, and discovers a treasure trove of novel species and genes. An international expedition that has combed the world’s oceans for new information about the mysterious plankton ecosystems at the base of the marine food chain is reporting its first findings this week…

Merck to Present Data at ASCO that Illustrate How the Company is Tackling Difficult – to – Treat Cancers

On Mai 15, 2015, Posted by , In Allgemein, With No Comments

New data on priority candidates from Merck’s oncology and immuno-oncology pipeline are being presented, including avelumab,  evofosfamide and tepotinib For further information please see http://news.merck.de/N/0/72047395FC832D35C1257E440053DCED/$File/ASCO2015CurtainRaiserEng.pdf

Merck and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti – PD – L1 Antibody

On Mai 13, 2015, Posted by , In Allgemein, With No Comments

Early data demonstrates advances in the understanding of investigational immuno-oncology therapy avelumab acrossmultiple tumor types Merck and Pfizer todayannounced multiple presentations on studies evaluating the preliminary safety andefficacy of avelumab* at the 2015 American Society of Clinical Oncology (ASCO) annualmeeting. Avelumab (also known as MSB0010718C) is an investigational fully human…